Physician profile
Cara Bennett
NPI 1679646327
$1,553.50
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $168 · 2023: $221 · 2024: $547 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $228.48 | 2023-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $183.01 | 2021-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $180.23 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.20 | 2021-2025 | Caplyta |
| Neurelis, INC. | $125.00 | 2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $103.53 | 2021-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $93.26 | 2025 | Jornay Pm |
| Corium, LLC | $74.06 | 2023-2024 | Azstarys |
| Lundbeck LLC | $61.64 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $56.72 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $44.45 | 2023-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $43.29 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $39.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2024-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $27.93 | 2022-2023 | Belsomra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.92 | 2024 | Rejoyn |
| Noven Therapeutics, LLC | $23.17 | 2024 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $17.14 | 2022 | |
| Eisai INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.